Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 14/20 | 0.50 |
| ▸ | NOS3 | P29474 | 10/20 | 0.48 |
| ▸ | NOS1 | P29475 | 10/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673405 | 1.00 | NOS2 (0.50) | NOS2NOS3NOS1 | |
| Acetic Acid SCHEMBL5930674 | 0.97 | NOS2 (0.48) | NOS2NOS3NOS1 | |
| SCHEMBL5930676 | 0.84 | NOS2 (0.45) | NOS2NOS3NOS1 | |
| SCHEMBL5672264 | 0.77 | NOS2 (0.48) | NOS2NOS3NOS1 | |
| SCHEMBL5672148 | 0.75 | NOS2 (0.46) | NOS2NOS3NOS1 | |
| SCHEMBL5672154 | 0.75 | NOS2 (0.46) | NOS2NOS3NOS1 | |
| SCHEMBL8327657 | 0.71 | NOS2 (0.66) | NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL7052386 | 0.70 | NOS2 (0.60) | NOS2NOS3NOS1 | |
| SCHEMBL5672165 | 0.69 | NOS2 (0.48) | NOS2NOS3NOS1 | |
| SCHEMBL5673375 | 0.69 | NOS2 (0.60) | NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194847-A1 | Novel 6-substituted 2-aminopyridine derivatives | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | claimed |
| EP-1611099-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | claimed |
| WO-2004087665-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | claimed |
| US-20060194847-A1 | Novel 6-substituted 2-aminopyridine derivatives | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | disclosed |
| EP-1611099-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087665-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194847-A1 | Novel 6-substituted 2-aminopyridine derivatives | NOS1, NOS2, NOS3 | NOS2 2/4885NOS3 3/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.